Brokers Offer Predictions for ADMA Biologics Inc’s Q3 2018 Earnings (ADMA)

Share on StockTwits

ADMA Biologics Inc (NASDAQ:ADMA) – Research analysts at Zacks Investment Research cut their Q3 2018 earnings estimates for ADMA Biologics in a note issued to investors on Monday, October 15th. Zacks Investment Research analyst J. Vandermosten now expects that the biotechnology company will post earnings per share of ($0.31) for the quarter, down from their previous estimate of ($0.29). Zacks Investment Research also issued estimates for ADMA Biologics’ Q4 2018 earnings at ($0.30) EPS and FY2018 earnings at ($1.33) EPS.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Friday, August 10th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The business had revenue of $4.66 million during the quarter, compared to the consensus estimate of $5.35 million. ADMA Biologics had a negative net margin of 119.34% and a negative return on equity of 89.78%.

ADMA has been the topic of several other research reports. Oppenheimer set a $13.00 price objective on ADMA Biologics and gave the company a “buy” rating in a research note on Tuesday, October 2nd. BidaskClub upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Wednesday, September 5th. Raymond James restated a “buy” rating and issued a $10.00 price objective (down previously from $11.00) on shares of ADMA Biologics in a research note on Friday, October 12th. Chardan Capital started coverage on ADMA Biologics in a research note on Monday, July 30th. They issued a “buy” rating and a $10.00 price objective on the stock. Finally, Maxim Group restated a “buy” rating and issued a $12.00 price objective on shares of ADMA Biologics in a research note on Wednesday. Seven analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus price target of $10.50.

NASDAQ:ADMA opened at $5.53 on Thursday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 8.88 and a current ratio of 10.65. The company has a market capitalization of $248.89 million, a price-to-earnings ratio of -2.90 and a beta of 2.35. ADMA Biologics has a 12-month low of $2.01 and a 12-month high of $6.96.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Northern Trust Corp increased its stake in shares of ADMA Biologics by 618.2% during the second quarter. Northern Trust Corp now owns 209,313 shares of the biotechnology company’s stock worth $944,000 after purchasing an additional 180,170 shares during the period. 683 Capital Management LLC increased its stake in shares of ADMA Biologics by 9.9% during the second quarter. 683 Capital Management LLC now owns 885,000 shares of the biotechnology company’s stock worth $3,991,000 after purchasing an additional 80,000 shares during the period. Bank of New York Mellon Corp increased its stake in shares of ADMA Biologics by 188.0% during the second quarter. Bank of New York Mellon Corp now owns 54,828 shares of the biotechnology company’s stock worth $247,000 after purchasing an additional 35,791 shares during the period. Ardsley Advisory Partners bought a new position in shares of ADMA Biologics during the second quarter worth approximately $361,000. Finally, Stonepine Capital Management LLC bought a new position in shares of ADMA Biologics during the second quarter worth approximately $3,751,000. Institutional investors own 55.08% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Featured Story: Why investors pay attention to retained earnings

Earnings History and Estimates for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Loom Network  Reaches Market Capitalization of $29.30 Million
Loom Network Reaches Market Capitalization of $29.30 Million
DeltaCredits Hits 24 Hour Volume of $0.00
DeltaCredits Hits 24 Hour Volume of $0.00
Zacks: Brokerages Expect Eventbrite Inc  Will Announce Quarterly Sales of $72.90 Million
Zacks: Brokerages Expect Eventbrite Inc Will Announce Quarterly Sales of $72.90 Million
Zacks: Analysts Expect Aramark  Will Announce Earnings of $0.64 Per Share
Zacks: Analysts Expect Aramark Will Announce Earnings of $0.64 Per Share
Zacks: Brokerages Anticipate QuinStreet Inc  Will Post Earnings of $0.12 Per Share
Zacks: Brokerages Anticipate QuinStreet Inc Will Post Earnings of $0.12 Per Share
Mixin  Price Tops $66.82
Mixin Price Tops $66.82


© 2006-2018 Ticker Report